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Abstract
Background: Human growth factor receptor bound protein 7 (Grb7) is an adapter protein that mediates
the coupling of tyrosine kinases with their downstream signaling pathways. Grb7 is frequently
overexpressed in invasive and metastatic human cancers and is implicated in cancer progression via its
interaction with the ErbB2 receptor and focal adhesion kinase (FAK) that play critical roles in cell
proliferation and migration. It is thus a prime target for the development of novel anti-cancer therapies.
Recently, an inhibitory peptide (G7-18NATE) has been developed which binds specifically to the Grb7 SH2
domain and is able to attenuate cancer cell proliferation and migration in various cancer cell lines.
Results: As a first step towards understanding how Grb7 may be inhibited by G7-18NATE, we solved the
crystal structure of the Grb7 SH2 domain to 2.1 Å resolution. We describe the details of the peptide
binding site underlying target specificity, as well as the dimer interface of Grb 7 SH2. Dimer formation of
Grb7 was determined to be in the µM range using analytical ultracentrifugation for both full-length Grb7
and the SH2 domain alone, suggesting the SH2 domain forms the basis of a physiological dimer. ITC
measurements of the interaction of the G7-18NATE peptide with the Grb7 SH2 domain revealed that it
binds with a binding affinity of Kd = ~35.7 µM and NMR spectroscopy titration experiments revealed that
peptide binding causes perturbations to both the ligand binding surface of the Grb7 SH2 domain as well
as to the dimer interface, suggesting that dimerisation of Grb7 is impacted on by peptide binding.
Conclusion: Together the data allow us to propose a model of the Grb7 SH2 domain/G7-18NATE
interaction and to rationalize the basis for the observed binding specificity and affinity. We propose that
the current study will assist with the development of second generation Grb7 SH2 domain inhibitors,
potentially leading to novel inhibitors of cancer cell migration and invasion.
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Background
Tyrosine kinase signaling pathways play a major role in
the regulation of cell growth, division and motility. It is
unsurprising, therefore, that aberrations of these path-
ways can underlie cancerous phenotypes [1,2] and that
tyrosine kinase pathways have been the targets of several
successful anti-cancer agents [3]. These targets have
included extracellular and cytoplasmic domains of recep-
tor tyrosine kinases, but downstream binding partners
may also prove to be important targets for new therapeu-
tics [4,5].
Grb7 is a member of a family of adapter proteins that
includes Grb10 and Grb14, and serves to couple activated
tyrosine kinases to downstream signaling pathways [6].
These proteins share a region with sequence homology to
the Mig-10 C. elegans gene required for migration of neu-
ronal cells in embryonic development, suggesting a role
for the Grb7 family in cell migration [7]. This role is con-
sistent the presence of Grb7 in focal adhesions, where it is
bound and phosphorylated by focal adhesion kinase
(FAK) in the process of cell migration [8,9]. Grb7 is also
found in the cytoplasm where it interacts with other
upstream binding partners [10,11] including the mem-
bers of the ErbB receptor family [12,13] whose activities
play a critical role in the regulation of cell proliferation
[14,15].
Although the precise downstream activities of Grb7 are
not yet known, there is compelling evidence that Grb7
represents an important new cancer target [16]. Grb7 is
frequently overexpressed in invasive and metastatic cell
lines. Grb7 is tightly co-amplified with the ErbB2 receptor
in breast cancer cell lines and there is a strong correlation
between ErbB2 and Grb7 over-expression in primary
breast cancer specimens [13], as well as in oesophageal
and gastric carcinoma [17,18]. Recent data suggest that
upregulation of Grb7 impacts on both the proliferative
and invasive potential of the cancer cells. An inhibitor
peptide specific for Grb7 was shown to inhibit breast can-
cer cell proliferation with no effect on non-malignant cells
[19]. In a separate study, the same Grb7 inhibitor was
demonstrated to significantly attenuate the migratory
potential of pancreatic cancer cells [20]. Grb7 is thus an
important candidate for the development of inhibitors
that block aberrant Grb7 downstream signaling in cancer
progression.
Members of the Grb7 family share a conserved multi-
domain structure comprising an N-terminal proline rich
domain, a Ras-associating-like (RA) domain, a plekstrin
homology (PH) domain, a C-terminal src-homology 2
(SH2) domain and a region between the PH and SH2
domains termed the BPS domain [21,22]. The interaction
with upstream tyrosine kinases is predominantly medi-
ated by the SH2 domain, which recognizes specific phos-
photyrosines. The adjacent BPS domain has also been
shown to contribute to recognition of the insulin and
insulin-like growth factor-1 receptors by Grb7 family
members [23,24]. Phosphotyrosine (pY) recognition
occurs via a highly positively charged pocket at the surface
of the SH2 domain [25,26]. Substrate differentiation is
conferred by amino acid residues immediately surround-
ing the phosphotyrosine and in particular those located
C-terminal to the phosphotyrosine [27].
Despite the SH2 domains of Grb7, Grb10 and Grb14 pro-
teins exhibiting between 62 – 72% sequence identity, the
domains recognise different phosphotyrosine containing
sequences. The Grb7 SH2 domain displays a strong pref-
erence for phosphotyrosines contained within a pYXN
motif, where X is any amino acid [28]. The presence of the
asparagine at the +2 position (relative to pY) is thought to
facilitate the formation of a turn in this region, enhancing
the interaction with the Grb7 SH2 domain [29]. In con-
trast, Grb14 SH2 domain recognition sequences contain a
hydrophobic residue at the +3 position relative to the
phosphotyrosine [30,31]. A consensus binding sequence
for the Grb10 SH2 domain has yet to be determined
although several pY binding sites have been identified,
including Tyr-771 of PDGF-Rβ, Tyr-929 of ELK and the
phosphorylated activation loop of the Insulin Receptor
[22,32-35].
Due to the implication of Grb7 in cancer cell progression,
an inhibitor specific for Grb7 SH2 domain has been
developed that targets the Grb7 SH2 pY peptide binding
site [28]. Such a peptide provides the opportunity to test
the role of Grb7 in cancer progression, and may poten-
tially lead to novel anti-cancer therapeutics [16]. The pep-
tide, termed G7-18NATE (Grb7-peptide18-No Arms
Thioether), was developed using phage display screening
for peptides able to specifically bind Grb7 SH2 [28]. G7-
18NATE bound to the Grb7 SH2 domain, but not to
Grb14 SH2 domain or to the Grb2 SH2 domain that has
also been shown to preferentially bind to a YXN motif.
Furthermore, in a recent study by Tanaka and colleagues,
G7-18NATE was shown to not only selectively block the
interaction between Grb7 and FAK in vivo, but to signifi-
cantly attenuate the migration of pancreatic cancer cells
[20]. In addition to effects on cell migration, cell permea-
ble G7-18NATE peptides have recently been shown by
Pero et. al. to inhibit the proliferation in a variety of dif-
ferent breast cancer cells with no effect on non-malignant
cells. Co-treatment of cell permeable G7-18NATE peptide
plus chemotherapeutic drugs Doxorubicin or Herceptin
resulted in significant reduction of the drug EC50 value in
breast cancer cells [19]. G7-18NATE thus represents the
first specific inhibitor of Grb7 and the first stage in the
development of a potential anti-cancer therapeutic. ThisBMC Structural Biology 2007, 7:58 http://www.biomedcentral.com/1472-6807/7/58
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Grb7 inhibitory peptide has potential to be developed as
a therapeutic agent alone, in combination with traditional
chemotherapy, or in combination with other targeting
molecules for treatment of cancer.
As a step towards determining the means by which Grb7
SH2 recognizes its specific pY peptide substrates and the
G7-18NATE peptide inhibitor we report the crystal struc-
ture of the human Grb7 SH2 domain to 2.1 Å resolution.
This facilitates the first high resolution comparison of the
Grb7 SH2 domain with Grb10 and Grb 14 SH2 domains,
allowing us to better understand the basis for their differ-
ential binding specificities [36,37]. We also describe the
structural basis for the previously reported Grb7 SH2
domain dimerisation [38,39] and show this also takes
place for full-length Grb7, with implications for the regu-
latory mechanism of Grb7 activity. Furthermore, we
present biophysical studies of the interaction between the
G7-18NATE peptide and the Grb7 SH2 domain, using iso-
thermal titration calorimetry and NMR spectroscopy,
which provide insight into the basis of their binding affin-
ity and specificity. Together, the data has allowed us to
propose a model of the interaction that may assist the fur-
ther development of potent and specific inhibitors of
Grb7.
Results
The overall structure of the Grb7 SH2 domain
As a first step towards describing the G7-18NATE/Grb7
interaction we solved the crystal structure of the Grb7 SH2
domain to 2.1 Å. This was achieved using molecular
replacement, employing the crystal structure of the
Grb10γ SH2 as a search model (PDB:1NRV [36]). The
final Grb7 SH2 model consists of four protein chains each
containing residues 420–532 of the human Grb7 protein,
181 water molecules and 7 sulphate anions, and has an R-
factor of 20.1% (Rfree = 25.5 %) (Table 1). Interpretable
electron density was missing for the 7 N-terminal residues
of the construct (GSPASGT) in all four chains. The side-
chains of several residues in the BC, DE and CD loops and
the αA helix were also omitted from the final model due
to poorly defined electron density. The pairwise α-carbon
root mean square deviations (r.m.s.d.) for the four pro-
tomers are between 0.23 and 0.95 Å.
The monomer fold of the Grb7 SH2 domain is typical of
the SH2 domain family, forming a βαβββββαβ configura-
tion [40] (Figure 1). The standard nomenclature for SH2
domain secondary structures devised by Eck et al. [41]is
adopted throughout this report. Thus the Grb7 SH2
domain comprises a central antiparallel β-sheet, formed
by the βB, βC and βD strands, which is sandwiched by the
two α-helices, αA and αB. An extension of the βD strand
(termed βD'), along with the βE strand, forms a second,
smaller anti-parallel β-sheet. An N-terminal helix was
observed prior to the start of the SH2 domain and desig-
nated the name H1. The βF strand, observed in other SH2
domains, does not form in Grb7.
Comparison with other SH2 domains and the Grb7 SH2 
NMR derived structure
The Grb7 SH2 domain superposes with Grb14
(PDB:2AUG; [37]) and Grb 10 (PDB:1NRV; [36]) SH2
domains, across Grb7 SH2 residues 431–523, with α-car-
bon r.m.s.d.s of 1.24 Å and 0.88 Å respectively. Relative to
the archetypal Src SH2 domain (1SPS; [42]) the Grb7 SH2
domain shows a slightly greater divergence due to loop
structure differences (α-carbon r.m.s.d. of 1.65 Å). This is,
in part, due to a three residue insertion in the acidic DE
loop characteristic of the Grb7 family members. The CD
loop is also shorter by five residues. This combination of
Table 1: Grb7 SH2 domain Data Collection and Refinement 
Statistics
Grb7 SH2
Data Collection
Space group P212121
Unit Cell (Å) a = 62.6
b = 63.9
c = 105.7
α = β = γ = 90°
Molecules in the ASU 4
Resolution range (Å)a 44 – 2.1 (2.18 – 2.1)
Observations 79384
Unique reflections 25401
Completeness (%)a 99.1 (99.4)
I/σa 12.6 (2.2)
Rmerge (%)a, b 8.4 (50.5)
Wilson B (Å)a 28.4
Refinement
Resolution limits (Å)a 30 – 2.10 (2.15 – 2.10)
No. of reflectionsa 23949 (1731)
Rcryst (%)a 20.1 (25.4)
Rfree (%)a, c 25.5 (28.9)
Protein atoms 3733
Water molecules 181
Other molecules 7 SO4
2-
r.m.s.d. from ideal values ideaiations
Bond lengths (Å) 0.014
Bond angles (°) 1.486
Average B-factors (Å)3
Protein 38.1
Water 40.6
Ions 58.7
aValues in parentheses are for the highest resolution shell happiness
bRmerge = Σ |I – < I >|/Σ I where I is the observed diffraction intensity of 
the jth observation of reflection hkl and < I > is the average diffraction 
intensity of all measurements of reflection hkl.
cRfree = Σ | |Fo|-|Fc|/Σ |Fo| where |Fo| and |Fc| are the observed and 
calculated factors respectively.BMC Structural Biology 2007, 7:58 http://www.biomedcentral.com/1472-6807/7/58
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differences is, to the best of our knowledge, unique to
Grb7 family SH2 domains.
The Grb7 SH2 structure differs markedly from that in
complex with the ErbB2 receptor derived peptide, pY1139
determined using NMR spectroscopy (1MW4, representa-
tive model 5; [29]) with the two structures overlaying for
residues 431–523 with an α-carbon r.m.s.d. value of 3.9 Å
(Figure 1C). The NMR derived Grb7 SH2 structure
appears to be loosely defined by the NMR derived con-
straints relative to other SH2 domain structures. More
importantly, however, the NMR structure deviates from
the crystallographic Grb7 SH2 domain in the region of the
DE loop which is not extended in the NMR structure, due
to an alternative hydrogen bonding network between the
βD' and βE sheets. This difference propagates to a rear-
rangement of the EF loop, βB helix and BG loop that fol-
low. Whilst it may be argued that these differences reflect
structural changes that occur upon pY peptide binding,
such dramatic structural rearrangements, that involve a
rearrangement of a hydrogen bond network, have not pre-
viously been observed upon peptide binding to SH2
domains, although subtler differences have [43-45].
Owing to the considerable differences between the NMR
Crystal structure of the Grb7 SH2 domain Figure 1
Crystal structure of the Grb7 SH2 domain. (a) Structure based sequence alignment of Grb7 SH2, Grb14 SH2 (2AUG; 
[37]) and Grb10 SH2 (1NRV; [36]). Secondary structure elements present in the Grb7 SH2 structure as determined by WHA-
TIF [71] are shaded from purple at the N-terminus to red at the C-terminus. Secondary structure elements of the canonical 
SH2 domain as defined by Eck et al. [41] are shown in green and orange symbols above the sequences. The boundaries of these 
elements differ slightly from that observed in the Grb7 SH2 domain. Residue number is for the Grb7 SH2 domain (b) Cartoon 
representation of the Grb7 SH2 domain shaded from purple at the N-terminus to red at the C-terminus. The extended DE 
loop distinguishes this family of SH2 domains from others. (c) A structural comparison of the Grb7 SH2 domain (green) with 
the Grb7 SH2 domain bound to an ErbB2 derived phosphopeptide (1MW4; black; [29]). The location of the bound phos-
phopeptide is indicated.BMC Structural Biology 2007, 7:58 http://www.biomedcentral.com/1472-6807/7/58
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derived Grb7 SH2 domain and all other SH2 domain
structures (ligand bound and unbound), we propose that
the current crystallographically derived structure is a more
accurate model of the Grb7 SH2 domain, and a better
starting point for modeling interactions with bound lig-
ands.
The ligand binding site assumes a bound BC loop 
conformation
The ligand binding site within SH2 domains comprises
the phosphotyrosine (pY) binding pocket and adjacent
peptide binding site that confers specificity for the resi-
dues immediately C-terminal to the pY [40]. The Grb7
SH2 pY binding pocket exists in a cleft formed by residues
in the central β-sheet, the αA and the BC loop (also
referred to as the phosphate binding loop) and possesses
a large positive potential for interacting with the phos-
photyrosine (Figure 2A). Although the BC loop within
apo-SH2 domain structures usually exhibits poorly
defined electron density [25], the Grb7 SH2 domain BC
loop is well defined and closely resembles that of SH2
domains in their peptide bound conformation. The BC
loop is held in this conformation by a complex network
of hydrogen bond contacts formed with a sulphate anion
that appears to mimic the phosphate moiety of the natural
ligand (Figure 2B). These contacts include a bidentate
ionic interaction with the side-chain of the invariant Arg
458 (βB5). Additional hydrogen bonds are formed with
the side-chains of Arg 438 (αA2), Ser 460 (βB7) and the
main-chain amide of Gln 461 (BC1).
The adjacent peptide binding site of the Grb7 SH2
domain differs from that observed in typical SH2
domains, such as the archetypal Src SH2 domain, which
bind phosphopeptides in an extended conformation [25].
In these SH2 domains, the side-chain of the +3 residue of
the phosphopeptide is accommodated within a hydro-
phobic pocket that is lined by residues in the BG and EF
loops, along with the βD strand and αB helix [26]. Analy-
sis of the molecular surface of the Grb7 SH2 domain indi-
cates that it lacks this classical +3 binding pocket. Instead,
it is filled by the side-chain of the BG3 residue (Ile 518
which forms a Van der Waals contact with the α-carbon of
the EF1 residue (Asp 496) sealing off the pocket. This is
consistent with the Grb7 SH2 domain binding a peptide
with a turn-containing structure as displayed by the Grb2
and Gads SH2 domains [46,47].
The Grb7 SH2 dimer interface
The Grb7 SH2 domain crystallised as a dimer, forming a
dimerisation interface (between chains A and B and
between chains C and D in the asymmetric unit) analo-
gous to that observed for Grb10 and Grb14 domain struc-
tures [36,37]. The Grb7 SH2 dimer is formed by the anti-
parallel arrangement of two SH2 domains with residues
in the βE strand, EF to FB loop region, αB helix and BG
loop contributing to the dimer interface (Figure 3). Phe
511 (αB8), the mutation of which has previously been
shown to abrogate Grb7 SH2 dimerisation [38], occupies
a key position at the centre of the dimerisation interface
forming hydrophobic contacts with its equivalent in the
The phosphate binding pocket of the Grb7 SH2 domain Figure 2
The phosphate binding pocket of the Grb7 SH2 
domain. (a) Electrostatic potential surface of Grb7 SH2 gen-
erated using CCP4MG [80]. Positively charged electrostatic 
potential is coloured blue and negatively charged electro-
static potential is coloured red. The positions of the phos-
phate binding pocket is indicated. (b) A 2Fo - Fc electron 
density map depicting the phosphate binding pocket of Grb7 
SH2. A sulphate ion co-crystallised in this pocket in all four 
molecules in the asymmetric unit. The map is contoured at 1 
σ. R438, R458, Q461 and S460 form direct contacts with the 
sulphate ion and are labeled. The side-chain of R462 lacks 
well defined density and is probably fairly mobile in the crys-
tal.BMC Structural Biology 2007, 7:58 http://www.biomedcentral.com/1472-6807/7/58
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opposing protomer (Phe 511*; note that residues in the
second protomer are designated by *) and the side-chains
of Thr 500*, Phe 502, and Asn 515 (αB12). The side-
chains of Thr 503 (FB1) and Leu* 514 (αB11) pack
together and this interaction caps the dimerisation inter-
face. Dimer formation is also stabilised by a number of
hydrogen bonds. Both OD1 and ND1 of Asn 515 (αB12)
form hydrogen bond contacts to the main chain atoms of
Arg 501*. The side-chain of Gln 507 (αB4) is hydrogen
bonded to the backbone carbonyl of Glu 510* (αB7*).
The side-chain of Glu 488 (DE3) was also found to form
two hydrogen bonds to the side-chain of Arg 524* (BG9*)
in one of the two dimers. A similar network of hydropho-
bic and hydrophilic interactions stabilises the Grb10 SH2
dimer [36]. The loss of accessible surface area upon dim-
erisation is about 500 Å2  per monomer, representing
approximately 7 % of the monomer surface area. The
intermolecular interactions between the two protomers
that make up the dimer may help define the positions of
residues in the BG and EF loops. This is reflected in the B-
factors of these residues (amino acids 496 – 499 and 516
– 524), which are lower than the B-factors determined for
residues in other loop regions.
A second dimerisation interface (between chains A and D)
was also observed within the asymmetric unit. This inter-
face is not formed within the crystal packing of other Grb7
family member SH2 domains. It occurs with a buried sur-
face area of approximately 400 Å2 per monomer and
involves contacts between the AA and BC loops and the
αA helix of the A chain, and the βD, βD' and βE strands
and the BC, DE and EF loops of the D chain. This buried
surface area is smaller than that between the AB and CD
dimers and is peculiar to this Grb7 SH2 domain crystal
form. Since this interface does not involve Phe 511,
shown to be critical to dimerisation in solution, we pro-
pose that this is not the dimer that predominates in solu-
tion.
Full-length Grb7 dimerises in vitro via its SH2 domain
The observation of dimer formation in the crystal struc-
ture prompted us to investigate the strength of the interac-
tion between Grb7 SH2 domains as well as between full-
length Grb7 molecules. The dimer dissociation constant
was calculated for both the Grb7 SH2 domain and full-
length Grb7 at 20°C using analytical ultracentrifugation.
Figure 4 shows profiles recorded for the two proteins that
could be fitted globally to a monomer-dimer self-associa-
tion model using NONLIN [48,49]. This yielded a disso-
ciation equilibrium constant for the Grb7 SH2 domain of
21.8  µM. This represents a slightly weaker association
than that determined in previously reported experiments
conducted at 4°C [38], consistent with the lesser role of
hydrophobic interactions at the higher temperature. The
profiles obtained for full-length Grb7 at 12 µM yielded a
dissociation equilibrium constant of 11 µM. Although
some sample heterogeneity, possibly due to protein aggre-
gation or degradation, prevented a simultaneous fit with
profiles recorded at higher concentrations, the data dem-
onstrated that full-length Grb7 forms dimers in vitro with
a similar affinity to that exhibited by the SH2 domain
alone. This suggests that the Grb7 molecule may exist as a
dimer in vivo via its SH2 domain, as also thought to occur
for the Grb10 and Grb14 molecules [36,37].
The G7-18NATE peptide binds Grb7 SH2 with micromolar 
affinity
The G7-18NATE peptide (Figure 5A) is the first non-phos-
phorylated peptide to be discovered with binding specifi-
city for the Grb7 SH2 domain. It has been found to bind
A stereoview of the Grb7 SH2 domain dimersiation Figure 3
A stereoview of the Grb7 SH2 domain dimersiation. 
(a) Cartoon representation of the Grb7 SH2 domain dimer. 
The secondary structure elements that form the dimerisation 
interface are labeled. (b) The Grb7 SH2 domain dimer inter-
face. Residues that form the dimerisation interface are 
shown. Hydrogen bonds are shown as broken lines. The 
interaction between R524 and E488 is absent from the AB 
dimer interface. In both panels the D chain is coloured yel-
low and indicated by a * and the C chain is coloured green.BMC Structural Biology 2007, 7:58 http://www.biomedcentral.com/1472-6807/7/58
Page 7 of 15
(page number not for citation purposes)
to the Grb7 SH2 domain, preferentially over the Grb14
SH2 domain, and have the capacity to interfere with Grb7
interactions with the ErbB family of receptors [28] and
FAK  in vivo [20]. These interactions may underlie the
observed inhibition of breast cancer cell proliferation and
decrease in cell migration of pancreatic cancer cells treated
with G7-18NATE, making it of considerable importance
to further characterise this peptide and its interactions
with Grb7 SH2 domain. Isothermal titration calorimetry
was thus used to determine the binding affinity of G7-
18NATE for the Grb7 SH2 domain (Figure 5B). This data
showed that the peptide bound to the SH2 domain with
Isothermal titration calorimetric measurement of G7- 18NATE peptide binding to the Grb7 SH2 domain (a) The  sequence of the G7-18NATE peptide used in this study Figure 5
Isothermal titration calorimetric measurement of 
G7-18NATE peptide binding to the Grb7 SH2 
domain (a) The sequence of the G7-18NATE peptide used 
in this study. (b) ITC data showing the titration of G7-
18NATE into Grb7 SH2. The samples were prepared in 50 
mM MES pH 6.6, 100 mM NaCl and 1 mM DTT. ITC experi-
ments were carried out in duplicate at 25°C with Grb7 SH2 
in the cell at 25 µM and G7-18NATE in the syringe at 440 
µM. The upper panel shows the raw data while the lower 
panel shows the data after peak integration and subtraction 
of the heat-of-dilution control. In this panel the grey line rep-
resents the fit to a 1:1 binding model.
Sedimentation equilibrium analysis of the Grb7 SH2 and  Grb7 Figure 4
Sedimentation equilibrium analysis of the Grb7 SH2 
and Grb7. (a) Absorbance at 280 nm verses radius data at 
sedimentation equilibrium for Grb7 SH2 at an initial loading 
concentration of 36 µM. The data collected at 14,000 rpm 
(circles), 16,600 rpm (squares), 24,300 rpm (diamonds) and 
28,800 rpm (triangles) were fitted simultaneously using the 
nonlinear regression program [48]. (b) Absorbance at 280 
nm verses radius data at sedimentation equilibrium for Grb7 
at an initial loading concentrations of 12 µM. The data col-
lected at 10,000 rpm (circles) and 11,800 rpm (squares) were 
fitted simultaneously using the nonlinear regression program 
NONLIN [77]. The solid line represents the calculated fit to a 
monomer-dimer model. The residuals of the fit are shown in 
the upper panels. Samples were in 50 mM MES pH 6.6, 100 
mM NaCl and 1 mM DTT. The experiments were conducted 
at 20°C.BMC Structural Biology 2007, 7:58 http://www.biomedcentral.com/1472-6807/7/58
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an affinity of Kd = ~35.7 µ M. This is only an order of mag-
nitude less than the Kd = 2.3 µM measured by Lyons and
co-workers for the binding of the Grb7 SH2 domain to
pY1139, a native phosphopeptide ligand derived from the
ErbB2 receptor [39].
The G7-18NATE peptide perturbs Grb7 SH2 residues at 
the peptide binding site and the dimerisation interface
In order to further characterize the Grb7 SH2 domain/G7-
18NATE interaction NMR titration experiments were used
to identify sites of Grb7 SH2 perturbation upon binding
by the G7-18NATE peptide. 1H-15N-HSQC spectra were
acquired for 15N-labelled Grb7 SH2 as G7-18NATE was
titrated in to slight excess (Figure 6A). Approximately 80%
of the amide crosspeaks exhibited line broadening, con-
sistent with an 'intermediate' rate of exchange of free and
bound forms of the protein (where the exchange rate is
close to the chemical shift differences of the resonances
between free and bound forms). Other peaks remained
unperturbed throughout the titration or exhibited a
chemical shift change rather than linebroadening. This
behavior is common for interactions for which the disso-
ciation constant is between 10-3 and 10-6 M.
This titration experiment revealed which residues of Grb7
SH2 domain are perturbed upon G7-18NATE binding.
Grb7 SH2 domain amide resonances have previously
been assigned and were kindly provided [50]. A plot of the
rate of change of signal intensity for each amino acid (as
a function of added peptide concentration) is shown in
Figure 6B. Those that broadened most rapidly (above the
mean value of R = 1.5 × 10-3) were considered significant.
Upon mapping these residues onto the structure of the
Grb7 SH2 domain, they clustered into two regions on the
protein surface (Figure 6C). The first region (red) is on the
peptide binding face of the domain, and includes residues
from the βC and βDβD' sheets as well as the EF loop.
These perturbations are similar in position to those
reported for the pY1139 peptide binding to Grb7 SH2
[50] and are consistent with the same binding site being
adopted by G7-18NATE.
The second region (green) occurs along the αB helix and
BG loop, which forms part of the dimerisation interface of
Grb7 SH2, where direct contacts with the peptide ligand
would not be expected to take place. Such perturbations
may result from impact of G7-18NATE binding on the
Grb7 SH2 domain dimer-monomer equilibrium. A shift
from dimeric to monomeric Grb7 SH2 domain has previ-
ously been reported upon binding by the pY1139 peptide
[50]. This was verified by NMR relaxation time measure-
ments, which reduced from 21.5 ns to 11.7 ns upon
pY1139 binding [39]. The perturbations at the Grb7 SH2
domain dimerisation interface upon G7-18NATE binding
G7-18NATE binding surface on the Grb7 SH2 domain Figure 6
G7-18NATE binding surface on the Grb7 SH2 
domain. (a) An overlay of the 15N, 1H-HSQC spectra of 
Grb7 SH2 alone (black) and in the presence of two molar 
equivalents of G7-18NATE (red). The insert shows changes 
to signals in the boxed region of the HSQC spectrum over 
the course of the titration. The ratio of G7-18NATE to Grb7 
SH2 is 0:1, 1:4, 1:2, 3:4, 1:1 and 2:1 in the black, red, blue, 
orange, purple and green spectra respectively. (b) The rate of 
change of peak volume over the titration series versus Grb7 
SH2 domain residue number. The broken line indicates the 
mean rate of change. Residues that exhibited rates of change 
greater than this value are coloured according to their loca-
tion in the Grb7 SH2 domain structure. (c) Surface represen-
tation of the Grb7 SH2 domain with residues affected by G7-
18NATE binding coloured. The majority of residues cluster 
onto either the phosphopeptide binding surface (red) or the 
dimerisation interface (green). Residues shown in blue were 
also affected by G7-18NATE binding but do not cluster on 
one surface. The two images are related by a 90° rotation 
about the horizontal axis of the page.BMC Structural Biology 2007, 7:58 http://www.biomedcentral.com/1472-6807/7/58
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are thus also likely to be due to a shift in equilibrium
towards the monomer.
Other Grb7 SH2 residues perturbed by G7-18NATE bind-
ing were located outside these two domains and may
result from distal structural rearrangements in these
regions resulting from the peptide binding. Interestingly,
no major perturbation of the Grb7 SH2 DE loop region
was observed in either our study of G7-18NATE, or the
study of pY1139 binding. It is thus unlikely that the con-
formational rearrangement of the DE loop reported in the
NMR derived structure of the Grb7 SH2/pY1139 peptide
complex occurs upon to peptide binding.
Model of the G7-18NATE/Grb7 SH2 complex
Together the structural data has allowed a model of the
G7-18NATE peptide interacting with the Grb7 SH2
domain to be constructed. In separate studies we have
shown that the G7-18NATE peptide has an intrinsic pro-
pensity for a turn conformation about the YDN motif
[51]. The current study also confirmed that G7-18NATE
binding impacts on the Grb7 SH2 domain surface in a
similar way to the pY1139 peptide, and is thus likely to
bind at the classical peptide binding site. A model of the
G7-18NATE peptide was hence positioned at the peptide
binding site of the crystallographically determined Grb7
SH2 domain structure by analogy to the Shc derived pep-
tide (PSpYVNVQN) which interacts with Grb 2 SH2
domain in a turn conformation (1JYR [52]) (Figure 7). In
this model Asn7, in the +2 position relative to Tyr5, is
positioned to form hydrogen bond interactions via its
sidechain carbonyl and amine functionalities with back-
bone NH and carbonyl groups of the βD6 residue. The
non-phosphorylated tyrosine (Tyr5) is able to adopt a
position in which its hydroxyl is positioned in the posi-
tively charged pY binding site. The aromatic ring of Tyr 5
forms Van der Waals contacts with the βD6 residue
sidechain (Leu 481) that may be important for the posi-
tioning of the peptide ligand. Glu3 is also positioned in
the pY binding site. Electrostatic interactions formed by
the Glu3 sidechain may compensate for the lack of a
phosphate moiety on the tyrosine. The side chain of Asp6
is oriented away from the binding cleft and is in proximity
of the backbone NH of the βD8 (His483) residue with
which it could form a hydrogen bond. Other residues,
constrained in a cyclical conformation, may make con-
tacts at the surface of βC, βD' and EF loop residues shown
to be perturbed by NMR spectroscopy. Whilst this model
should remain speculative, it suggests a likely basis for the
relatively high affinity and specific interaction between
G7-18NATE and the Grb7 SH2 domain.
Discussion
The Grb7 SH2 domain has been identified as a potential
target for the development of agents to reduce the invasive
potential of cancer cells in which Grb7 is overexpressed.
Its crystal structure to 2.1 Å resolution provides structural
detail for understanding the basis of interaction with nat-
ural targets and designed inhibitors. We have shown that
the Grb7 SH2 domain adopts the classic SH2 domain fold
excepting, as also observed for Grb10 and Grb14 SH2
domains, an extension of the βD' and βE strands resulting
Model of the Grb7 SH2/G7-18NATE complex Figure 7
Model of the Grb7 SH2/G7-18NATE complex. (a) The 
modeled structure of the complex. The Grb7 SH2 domain is 
shown in grey in cartoon representation and G7-18NATE in 
stick representation with carbon atoms coloured green. The 
positions of the two α-helices are indicated. The model was 
prepared using the structure of the Grb2 SH2:pYVN com-
plex (1JYR; [52]) as a template and energy minimised using 
NAMD [79]. (b) A close up of the Grb7 SH2/G718-NATE 
interface. The Glu3 and Tyr5 side-chains occupy the phos-
phate binding pocket while the Asn7 side-chain occupies a 
second pocket in the specificity determining region of the 
domain. Only Glu3, Tyr5, Asp6 and Asn7 are shown for clar-
ity.BMC Structural Biology 2007, 7:58 http://www.biomedcentral.com/1472-6807/7/58
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in a longer DE loop [36,37,42]. Along with residues in the
EF loop and αB helix, the extended DE loop contributes to
the dimerisation Grb7 SH2 domain. Also like the Grb10
and Grb14 SH2 domains, the Grb7 SH2 domain +3 pY
peptide binding site is occluded, suggesting that peptides
are preferentially bound in a turn-like conformation
[36,37].
Despite the similarity of the Grb7/10/14 SH2 domains
only Grb7 shows preferential binding for a YXN motif
[6,28,53]. Grb7 SH2 is reported to interact strongly with
Tyr-1139 (YVNQ) of the ErbB2 receptor while Grb14 does
not [54,55]. Furthermore, the G7-18NATE peptide,
selected on the basis of its YXN motif, was shown to bind
to the Grb7 SH2 domain but not to the Grb14 SH2
domain [28]. A key mutagenesis study investigating the
molecular basis for ErbB2 receptor binding by Grb7
revealed the critical role of the βD6 residue (Leu 481) in
Grb7 SH2 domain target recognition [55]. When this res-
idue was mutated to the Grb14 equivalent residue (Leu -
> Gln), binding to the ErbB2 receptor was completely
abrogated. Conversely, the mutation of the βD6 residue of
Grb14 SH2 domain to the Grb7 equivalent residue (Gln -
> Leu) imparted it with high affinity for ErbB2. The Leu
481 residue thus holds the key to Grb7 SH2 domain bind-
ing specificity.
The current structural data allows the impact of the βD6
residue on the structure of Grb7 SH2 domain to be exam-
ined. The βD6 residue occurs at the peptide binding inter-
face at the "specificity determining region" alongside the
phosphotyrosine binding pocket. By analogy to the inter-
action between the Grb2 SH2 domain and pYXN contain-
ing phosphopeptides, the βD6 residue forms critical
hydrogen bond contacts with the side-chain functionali-
ties of the +2 Asn via both its backbone NH and carbonyl
moieties [46,52,56]. This is consistent with the perturba-
tion of residue 481 observed upon the titration of G7-
18NATE as detected in the current NMR experiment. Inter-
estingly, a direct structural comparison of the crystallo-
graphically determined Grb7 and Grb14 SH2 domains
shows that the βD6 residue backbone atoms are equiva-
lently positioned in Grb7 and Grb14. Thus no direct dis-
turbance to the formation of hydrogen bonds to the +2
Asn would be expected to occur when the βD6 residue is
a Gln rather than a Leu. Instead, Grb7 binding to a YXN
motif is likely to be impacted on by the position and
chemical nature of the βD6 residue sidechain. The
sidechain of βD6 residue forms part of the phosphotyro-
sine binding pocket and it may be that subtle changes to
the phosphotyrosine binding position, caused by muta-
tion of the βD6 residue from a Leu to a Gln, results in the
observed loss of affinity for a YXN motif.
The Grb7 SH2 domain was found to be dimeric in the
crystal structure and in solution, forming an analogous
dimerisation interface to that observed for Grb10 and
Grb14 SH2 domains [36-39]. Dimerisation of full-length
Grb7 was demonstrated to occur in solution with a Kd of
the same order of magnitude as that obtained for the SH2
domain alone. This suggests that the Grb7 SH2 domain
forms the principle dimerisation interface within the
Grb7 dimer. A similar conclusion was reached for Grb10
by Hubbard and co-workers who found that mutation of
Phe 515 to an Arg in full-length Grb10γ (the mutation
which produced monomeric Grb10 SH2 domain) gener-
ates a monomeric form of the full-length protein [36].
The physiological importance of Grb7 SH2 domain dim-
erisation is still uncertain. It has been suggested for Grb10
and Grb14, that the dimeric state of the protein may con-
tribute to a cooperative association of two Grb molecules
to form a dimeric activated tyrosine kinase receptor
[36,37]. More recently it has been shown that Grb14
binding to the insulin receptor is enhanced by its dimeri-
sation [37]. In this and other studies, however, it has been
shown that peptide binding by the Grb7 SH2 domain
impacts on the dimer interface and shifts the dimer-mon-
omer equilibrium towards the monomer [39,50].
Whether Grb14 and Grb10 also undergo a dimer to mon-
omer transition upon peptide binding is yet to be ascer-
tained, but this would seem to be in conflict with
enhanced tyrosine kinase receptor binding by dimer for-
mation. It may be that a dimer to monomer transition
upon peptide binding is #peculiar to Grb7.
The structure of the Grb7 SH2 domain, elucidated by our
crystallographic study, has permitted its interaction with a
recently developed inhibitor peptide to be examined
more closely. The G7-18NATE peptide is an important
lead peptide in the development of novel therapeutics tar-
geting cancer cell migration [20,28]. We report a binding
affinity of Kd = ~35.7 µM. Only an order of magnitude
lower affinity than that measured for the pY1139 peptide
with Grb7 SH2 domain [39], it represents a relatively high
affinity interaction for a non-phosphorylated peptide. In
general the affinity of an SH2 domain/non-phosphor-
ylated peptide interaction is 104 – 105 times weaker than
the affinity measured for the binding of the SH2 domain
to a phosphorylated form of the peptide, with the differ-
ence in the total free energy of complex formation largely
the result of the electrostatic interactions between the SH2
domain and the phosphate moiety [57,58]. The lack of an
electrostatic interaction with a phosphate group may be
partially compensated for by the entropic advantage of the
cyclized structure of the peptide.
A modeled interaction of the G7-18NATE peptide with
the Grb7 SH2 structure, consistent with both the crystal-BMC Structural Biology 2007, 7:58 http://www.biomedcentral.com/1472-6807/7/58
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lographic and NMR derived data, provides a starting point
for understanding the structural basis for the binding spe-
cificity observed. As discussed above, the positioning of
Tyr 5 against the βD6 (Leu 481) sidechain of Grb7 SH2
may be critical for constructive interactions with the YDN
motif. The modeled interaction also demonstrates that the
lack of a phosphate moiety on the Tyr5 of G7-18NATE
may be partly compensated for by electrostatic interac-
tions between the Glu3 and the positively charged cleft.
Whilst glutamate is often used as a pY mimetic, here it
may contribute to binding alongside a non-phosphor-
ylated tyrosine. Asp 6 at the +1 position is also likely to be
favoured due to its accommodation without steric hin-
drance in a pocket of the Grb7 SH2 surface with potential
for the formation of hydrogen bond contacts. Based on
these observations, second generation peptides and pep-
tidmimetic molecules are currently being developed to
potently and selectively inhibit Grb7 in vivo.
Conclusion
The crystallographically determined structure and dimer
formation of the Grb7 SH2 domain has been described
providing a new level of insight into Grb7 target specifi-
city and the likely basis of Grb7 dimer formation in vivo.
The interaction of Grb7 SH2 domain with a non-phos-
phorylated inhibitor peptide (G7-18NATE) has been
examined, revealing that this peptide binds with unex-
pectedly high affinity at the classical peptide binding site
and that this impacts upon the dimerisation status of the
molecule. The structural basis for their interaction has
been modeled based on the biophysical data and repre-
sents a starting point for the development of second gen-
eration inhibitors of Grb7 based cancer cell migration and
proliferation.
Methods
Protein preparation
The pGex2T plasmid containing the Grb7 SH2 insert
(encoding residues 415-532 of human Grb7) was
obtained from Dr. Roger Daly [55]. Unlabelled Grb7 SH2
was expressed as a GST fusion protein in Escherichia coli
strain BL21(DE3).pLysS as previously described [38]. 15N-
labelled Grb7 SH2 was overexpressed in minimal media
containing 15NH4Cl as its only nitrogen source, using a
method similar to that described by Cai and co-workers
[59]. Both Grb7 SH2 preparations were purified using glu-
tathione affinity chromatography and cation exchange
chromatography following thrombin cleavage of the Grb7
SH2 domain from GST. The molecular mass of the puri-
fied unlabelled Grb7 SH2 domain was confirmed using
MALDI-TOF mass spectrometry performed by Proteomics
International (East Perth, WA, Aus) (Mexpected = 13,672 g/
mol, Mobserved = 13,687 g/mol,).
Full-length Grb7 (residues 1 – 532) was subcloned from
the mammalian expression vector pRc/CMV into the
pGex6P2 expression vector. The identity of the construct
was confirmed by DNA sequencing and the construct was
used to transform the E. coli strain BL21(DE3).pLysS. All
cultures were grown in LB containing 100 µg/ml ampicil-
lin and 25 µg/ml chloramphenicol. Full-length Grb7 was
expressed as a GST fusion and purified using glutathione
affinity chromatography. Full-length Grb7 was removed
by on column cleavage with PreScision protease (Amer-
sham) and further purified using cation exchange chro-
matography. The molecular mass of the purified full-
length Grb7 was confirmed using MALDI-TOF mass spec-
trometry (Mexpected = 60,457 g/mol, Mobserved = 60,415 g/
mol).
The purified proteins were dialyzed into 50 mM MES (pH
6.6), 100 mM NaCl and 1 mM DTT, concentrated and
stored at 4°C. The final concentrations were determined
spectrophotometrically at A280 using an extinction coeffi-
cient of 8250 M-1 (Grb7 SH2) and 49500 M-1 (full-length
Grb7) [60].
Preparation of G7-18NATE
G7-18NATE (cyclo-(CH2CO-WFEGYDNTFPC)-amide)
was synthesised manually using Fmoc chemistry and
standard solid phase peptide synthesis using RINK resin
[61] according to the method described by Pero et al. [28].
The peptide was subjected to N-terminal chloroacetyla-
tion following the protocol described in Lung et al. [62]
for the preparation of cyclised G7-18NATE. After cleavage
the peptide was cyclised over 48 h in water, with the pH
adjusted to > 8 with triethylamine. The cyclised product
was lyophilised and purified using reverse phase HPLC
and its mass confirmed by mass spectrometry (Mexpected =
1417.6 g/mol, Mmeasured = 1417.8 g/mol).
Crystallization and data collection
The Grb7 SH2 domain was crystallized using the hanging
drop vapor diffusion method. 2 µl of protein solution
(6.5 mg/ml) was mixed with 1 µl of reservoir solution
(100 mM sodium citrate (pH 6.1), 22.5% PEG 4000, 0.2
M ammonium sulphate and 5% glycerol) and incubated
over 1 ml of reservoir solution at 22°C. Crystals typically
grew within 4 days as square plates with dimensions of
100 × 100 × 30 µm3. Crystals were flash-cooled in a nitro-
gen stream at 100 K and mounted using cryo-loops on a
Rigaku RU-H2R rotating anode Cu Kα source (40 kV, 100
mA) equipped with focusing optics and a Mar345dtb
image plate detector. X-ray diffraction data were measured
to a resolution of 2.1 Å and integrated and scaled with
DENZO and SCALEPACK [63]. Structure factor ampli-
tudes were calculated using TRUNCATE [64]. The diffrac-
tion data was consistent with the space group P212121,BMC Structural Biology 2007, 7:58 http://www.biomedcentral.com/1472-6807/7/58
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with unit cell dimensions a = 62.6 Å, b = 63.9 Å, c = 105.7
Å. The data collection statistics are given in Table 1.
Structure determination and refinement
Unless otherwise stated all programs used for structural
and crystallographic analysis were located within the
CCP4 interface [65] to the CCP4 suite [66]. The structure
of Grb7 SH2 domain was solved by the molecular replace-
ment method. Initial phases were obtained using MOL-
REP [67] and the co-ordinates of the Grb10 SH2 domain
dimer as the search model (PDB:1NRV, [36]). Attempts to
use the NMR model of the Grb7 SH2 domain
(PDB:1MW4, [29]) to generate a molecular replacement
solution proved unsuccessful. Manual model rebuilding
was carried out in O [68] and maximum likelihood refine-
ment was carried out using REFMAC5 [69]. Non-crystallo-
graphic symmetry (NCS) restraints were applied between
the four chains that occupied the asymmetric unit but
were removed for the final round of refinement. Succes-
sive rounds of refinement and manual building were per-
formed until peaks no greater than 4σ or less than -4σ
were present in a |FO| - |Fc| electron density map. Ordered
water molecules were initially added to the model using
ARP waters from within REFMAC5 (ARP/wARP version
5.0; [70]) and later were added by hand. Only solvent
molecules that were located within good 2Fo - Fc electron
density and had acceptable hydrogen bonding geometry
contacts with either protein or existing solvent were
retained in the final model. Sulphate anions were built
into regions of tetrahedral shaped electron density. The
refinement statistics are reported in Table 1 and the
atomic coordinates have been deposited with the Protein
data bank. The programs WHATIF [71] and PROCHECK
[72] were used to assess the quality of the final structures.
Intermolecular contacts were calculated using CONTACT.
Buried surface area was calculated using AREAIMOL [73].
The coordinates have been deposited at the RCSB data-
base PDBID: 2QMS.
Analytical ultracentrifugation
Grb7 SH2 domain and full-length Grb7 were analysed at
loading concentrations of A280 values of 0.1, 0.3 and 0.6.
Sedimentation equilibrium experiments were performed
at 20°C in an Optima XL-A analytical ultracentrifuge
(Beckman Coulter, Fullerton, CA, USA) at rotor speeds of
14,000, 16,600, 24,300 and 28,800 rpm for Grb7 SH2
and 11,800 and 17,300 rpm for full-length Grb7. Cells fit-
ted with conventional Yphantis 12-mm six-channel equi-
librium centrepieces [49] and quartz windows were used.
Absorption profiles were recorded at 280 and 360 nm
with automatic dialysate absorption compensation. The
data were recorded in 0.001-cm steps and ten scans were
averaged to produce each profile. The system was deemed
to be in equilibrium when profiles recorded 4 h apart were
identical. The data were analysed by fitting models of
association to the absorbance versus radial position distri-
bution using the program NONLIN [48,49]. The partial
specific volumes of Grb7 SH2 domain and full-length Grb
7, calculated from their reported primary sequence, were
0.736 and 0.731 mL/g respectively. The density of the
buffer solution was calculated to be 1.00379 g/ml using
the program SEDNTERP v1.08 [74].
Isothermal titration calorimetry (ITC)
ITC experiments were performed on a VP-ITC Microcalo-
rimeter (Microcal, Northampton, MA, USA). Grb7 SH2
domain was dialysed extensively against 50 mM MES (pH
6.6), 100 mM NaCl and 1 mM DTT at 4°C. Lyophilised
G7-18NATE was dissolved in the final dialysate and the
pH adjusted to 6.6 using 0.1 M NaOH. The reference
power was set to 10 µCal/sec and the cell contents were
stirred continuously at 310 rpm throughout the titrations.
G7-18NATE (440 µM) was titrated into Grb7 SH2 (25
µM) in 30 8 µL injections at 25 °C, with a 5 min delay
between each injection, and the heat changes were moni-
tored. A binding isotherm was generated by plotting the
heat change evolved per injection against the molar ratio
of G7-18NATE to Grb7 SH2. Following baseline correc-
tion for heats of dilution (G7-18NATE injected into buffer
alone), the binding isotherm was fit by a single binding
site model using a non-linear least squares method, using
Origin (Microcal Software, Northampton, MA, USA).
During fitting the stoichiometry (n) was fixed at 1 while
the binding constant (Kd) and heat of binding (∆H) were
allowed to float.
NMR spectroscopy: 15N-Grb7 SH2 and G7-18NATE HSQC 
titration experiment
Purified  15N-Grb7 SH2 was dialysed against 50 mM
sodium acetate, 100 mM NaCl, 5 mM DTT, 1 mM EDTA,
1 mM NaN3 pH 6.6 at 4°C and concentrated to 850 µM.
Lyophilised G7-18NATE was dissolved in the final dia-
lysate retained from the preparation of 15N-Grb7 SH2. Its
pH was adjusted to 6.6 using 1 M NaOH and concentra-
tion adjusted to 5 mM as determined spectrophotometri-
cally using a molar extinction coefficient of 6970 M-1cm-1.
To each final NMR sample, D2O was added to a final con-
centration of 10 % (v/v).
NMR experiments were performed at 298 K on a Bruker
Avance 600 operating at a 1H resonance frequency of
600.13 MHz using a 5 mm TXI probe (1H, 13C and 15N)
equipped with XYZ-triple gradient capabilities (Bruker).
1H,15N-HSQC spectra were acquired using adapted ver-
sions of the published pulse sequences [75,76]. Water
suppression was achieved by replacing the final 90° pulse
with a Watergate sequence [77]. The 15N-decoupling dur-
ing acquisition was achieved using the GARP decoupling
scheme [78]. The 1H carrier frequency was set to that of
the water resonance and the 15N carrier frequency was setBMC Structural Biology 2007, 7:58 http://www.biomedcentral.com/1472-6807/7/58
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at a frequency between the Arg Nε and backbone amide
resonances. Spectral widths of 12.25 ppm (1H) and 40.0
ppm (15N) were used. Between 32 – 64 scans per incre-
ment were collected over 512 t1increments of 1024 com-
plex data points. The spectra were processed on a Silicon
graphics O2  workstation using XWINNMR software
(Bruker). The 1H frequency was referenced to the water
signal at 4.80 ppm, calibrated externally using TSP. The
digital resolution was enhanced by zero filling to 2048 ×
2048 (F2 × F1) real data points. The spectral resolution of
the 15N,1H-HSQC spectra was enhanced by apodisation
with a Lorentz-Gauss function in both dimensions. Base-
lines corrections were applied by subtraction of an auto-
matically calculated polynomial. Cross-peak volume was
calculated using the integration function within the
XWINNMR software (Bruker).
Molecular modeling of the G7-18NATE – Grb7 SH2 
complex
The G7-18NATE peptide was constructed using O [68]
with the thioether bond generated by defining appropri-
ate topology and parameter files. The peptide was posi-
tioned at the surface of the Grb7 SH2 model determined
crystallographically by analogy to the interaction between
the Shc derived peptide (PSpYVNVQN) interaction with
Grb 2 SH2 domain (1JYR; [52]). The structure was sub-
jected to positional refinement using NAMD [79] to
ensure there were no steric clashes in the final model.
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